Zai Lab Presentations at AACR 2024 Annual Meeting to Showcase Ongoing Clinical Studies in Key Global Oncology Programs

2024-04-02

临床1期AACR会议抗体药物偶联物

Poster sessions to highlight Phase 1 trials of internal oncology candidates ZL-1310, a next-generation antibody-drug conjugate for small cell lung cancer and other DLL3+ solid tumors DLL3+ solid tumors, and ZL-1218, an anti-CCR8 antibody for advanced solid tumors These internally discovered programs underscore the Company’s focus on extending oncology R&D innovation to people with cancer worldwide SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that two poster presentations highlighting ongoing global clinical studies in its oncology pipeline will be presented at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 taking place April 5-10, 2024, in San Diego, California. The global oncology programs to be showcased at AACR 2024 include a Phase 1a/1b study of ZL-1310 (NCT06179069), a novel antibody-drug conjugate (ADC) within the Zai Lab pipeline that targets the Delta-like ligand 3 (DLL3), a validated therapeutic target for the treatment of small cell lung cancer (SCLC). ZL-1310 is designed with a novel linker-payload platform TMALIN® which leverages the tumor microenvironment to overcome challenges associated with first-generation ADC therapies. Also featured at AACR 2024 will be Zai Lab’s Phase 1 study (NCT05859464) of ZL-1218, an anti-CCR8 antibody that blocks regulatory T cells (Treg) which suppress antitumor immunity in tumor tissue and is designed to deplete Treg cells selectively in tumors and minimally in other tissue. “These ongoing global clinical studies underscore Zai Lab’s continued commitment to pursue both novel and validated cancer biology targets and advance innovative oncology therapies that can potentially reach patients around the world,” said Rafael G. Amado, M.D., President, Head of Global Oncology Research and Development, Zai Lab. “We are dedicated to advancing the pipeline through both drug discovery and partnerships to address therapeutic challenges and unmet patient needs. As we extend the impact of our R&D innovation on a global scale, we look forward to highlighting these programs from our differentiated oncology pipeline at AACR 2024.” Details regarding the Zai Lab poster presentations at AACR 2024 are as follows: Title: Trial in Progress: A Phase 1a/1b, An Open-label, Multicenter Study of ZL-1310 to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Small Cell Lung Cancer Presenter: Linda Liu, Ph.D., Senior Vice President, Biologics Discovery, Zai Lab Session: PO.CTP01.02 - Phase I Clinical Trials in Progress 2, CT155 / 6 Date/Time: Monday, April 8, 2024, 1:30 PM - 5:00 PM PT Location: San Diego Convention Center Title: Trial in Progress: A Phase I, Open-label, Multicenter Study of ZL-1218, an anti-CCR8 IgG1, as a Single Agent and as Combination Therapy with Anti-PD-1 Antibody to Evaluate the Safety, Tolerability, and Pharmacokinetics in Subjects with Advanced Solid Tumor Presenter: Maria Tea, M.D., Senior Medical Director, Zai Lab Session: PO.CTP01.02 - Phase I Clinical Trials in Progress 2, CT162 / 13 Date/Time: Monday, April 8, 2024, 1:30 PM - 5:00 PM PT Location: San Diego Convention Center About Zai Lab Zai Lab (NASDAQ: ZLAB; HKEX: 9688) is an innovative, research-based, commercial-stage biopharmaceutical company based in China and the United States. We are focused on discovering, developing, and commercializing innovative products that address medical conditions with significant unmet needs in the areas of oncology, autoimmune disorders, infectious diseases and neuroscience. Our goal is to leverage our competencies and resources to positively impact human health in China and worldwide. For additional information about Zai Lab, please visit or follow us at . Zai Lab Forward-Looking Statements This press release contains forward-looking statements relating to our future expectations, plans, and prospects, for Zai Lab, including, without limitation, statements relating to our prospects and plans for developing and commercializing product candidates in our oncology pipeline, including ZL-1310 and ZL-1218 and the progress of related clinical trials, the potential benefits of ZL-1310 and ZL-1218, and the potential treatment of SCLC and other solid tumors. These forward-looking statements may contain words such as “aim,” “anticipate,” “believe,” “could,” “estimate,” “expect,” “forecast,” “goal,” “intend,” “may,” “plan,” “possible,” “potential,” “will,” “would,” and other similar expressions. Such statements constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not statements of historical fact or guarantees or assurances of future performance. Forward-looking statements are based on our expectations and assumptions as of the date of this press release and are subject to inherent uncertainties, risks, and changes in circumstances that may differ materially from those contemplated by the forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including but not limited to (1) our ability to successfully commercialize and generate revenue from our approved products, (2) our ability to obtain funding for our operations and business initiatives, (3) the results of our clinical and pre-clinical development of our product candidates, (4) the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approvals of our product candidates, (5) risks related to doing business in China, and (6) other factors identified in our most recent annual and quarterly reports and in other reports we have filed with the U.S. Securities and Exchange Commission (SEC). We anticipate that subsequent events and developments will cause our expectations and assumptions to change, and we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. These forward-looking statements should not be relied upon as representing our views as of any date subsequent to the date of this press release. Our SEC filings can be found on our website at and on the SEC’s website at .